Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Regulatory Routine −

Lophos Holdings Inc. Provides Corporate Update and Strategic Outlook

Dormant Psychedelic Developer Grapples with License Loss and Ongoing Trading Halt

By The Northwire Desk — AI Analysis Jun 11, 2026 · 21:08 MESC · 0.01 Lophos Holdings Inc.
Executive Summary
  • Lophos Holdings Inc. announced a corporate update and strategic outlook on June 11, 2026.
  • The company appointed Joshua Herman as CEO and added Brad Cotton and Dr. Cory Harris to the Board of Directors.
  • The Audit Committee was restructured with Brad Cotton as Chair, alongside Herman and Harris, both designated as independent directors.
  • The company lost its site-specific Controlled Substances Dealer's Licence (CSDL) following the disposition of its Napanee, Ontario facility through mortgage enforcement proceedings.
  • Management is evaluating third-party partnerships, collaborations with existing license holders, and contract research organizations to resume regulated activities.
  • Trading on the Canadian Securities Exchange remains halted due to a failure-to-file cease trade order (FFCTO) issued by the BC Securities Commission on September 5, 2024.
  • Management is prioritizing the completion of outstanding continuous disclosure requirements to seek revocation of the FFCTO and restore trading status.
Material Impact
  • The loss of the CSDL is a direct operational consequence of the facility's mortgage enforcement, which was already known or highly probable given the enforcement proceedings.
  • The strategic pivot to an asset-light, third-party partnership model is a logical response to losing physical infrastructure, but it does not generate immediate revenue or cash flow.
  • The FFCTO remains in effect, meaning the stock is effectively untradeable for public investors. This severely limits any price discovery or capital raising ability.
  • Leadership changes provide a governance reset, but without resolved regulatory compliance or a secured license, the impact on valuation is negligible.
  • The stock has traded at a flat $0.01 for over a year, indicating the market has already priced in the dormancy and regulatory issues.
MESC · Price
Company Overview
  • Lophos Holdings Inc. is a Canadian entity previously focused on the research and development of controlled substances, including MDMA, ketamine, LSD, DMT, mescaline, psilocin, and psilocybin.
  • Operations were centralized at a 10,000-square-foot facility in Napanee, Ontario, which has since been disposed of via mortgage enforcement.
  • The company is transitioning from a vertically integrated research model to an asset-light strategy leveraging external license holders and contract research organizations.
Read the original news release →

More from Lophos Holdings Inc.

Jul 01, 2026 · 10:20

Regulatory Survival Financing Keeps Halted Psychedelic Micro-Cap Afloat Amid CSDL Loss

Financings